Topline results from an investigator-initiated trial in Brazil show that treatment with Kintor Pharmaceutical’s proxalutamide cut mortality risk by 92 percent and significantly shortened the median length of hospital stay by nine days compared with standard of care in hospitalized patients with coronavirus disease 2019.
The U.S. National Institutes of Health (NIH) halted a trial of convalescent blood plasma in the treatment of patients with mild-to-moderate Covid-19 symptoms as it was unlikely to benefit this group.
People who have received the full course of Covid-19 vaccines can skip the standard 14-day quarantine after exposure to someone with the infection as long as they remain asymptomatic, U.S. public health officials advised.
A roundup of scientific studies on the novel coronavirus and efforts to find treatments and vaccines includes research on Covid-19 patients who still have symptoms 6 months after falling ill.
Blocking TNF production could offer a more effective solution for the treatment of COVID-19.
Using blood plasma from Covid-19 survivors to treat patients with severe pneumonia caused by the novel coronavirus showed little benefit, according to data released from a clinical trial in Argentina.
Researchers at Washington University School of Medicine in St. Louis published the results of a clinical trial evaluating an antidepressant, fluvoxamine, for early treatment for Covid-19.
In a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines, Covid-19 antibodies last at least three months and so do symptoms for many.
U.S. President Donald Trump had no Covid-19 symptoms for the past 24 hours, with a physical examination and his vital signs showing his condition remains sable, White House physician Sean Conley said.
Regeneron Pharmaceuticals Inc.’s experimental two-antibody cocktail reduced viral levels and improved symptoms in non-hospitalized Covid-19 patients.